Ewing sarcoma—diagnosis, treatment, clinical challenges and future perspectives

SK Zöllner, JF Amatruda, S Bauer, S Collaud… - Journal of clinical …, 2021 - mdpi.com
Ewing sarcoma, a highly aggressive bone and soft-tissue cancer, is considered a prime
example of the paradigms of a translocation-positive sarcoma: a genetically rather simple …

The nitrogen mustards

MS Highley, B Landuyt, H Prenen, PG Harper… - Pharmacological …, 2022 - Elsevier
The nitrogen mustards are powerful cytotoxic and lymphoablative agents and have been
used for more than 60 years. They are employed in the treatment of cancers, sarcomas, and …

[PDF][PDF] Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

SJ Strauss, AM Frezza, N Abecassis, J Bajpai… - Annals of …, 2021 - Elsevier
Highlights•This Clinical Practice Guideline provides key recommendations on the
management of bone sarcomas.•Recommendations have been agreed following a …

Phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic Ewing sarcoma: A Children's Oncology Group …

PJ Leavey, NN Laack, MD Krailo, A Buxton… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE The primary aim of this phase III randomized trial was to test whether the addition
of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed …

[HTML][HTML] A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies

SM Federico, AS Pappo, N Sahr, A Sykes… - European Journal of …, 2020 - Elsevier
Background Talazoparib combined with irinotecan and temozolomide demonstrated efficacy
in a murine Ewing sarcoma model. Based on these data, we conducted a phase I trial of …

Current status of management and outcome for patients with Ewing sarcoma

AC Hesla, A Papakonstantinou, P Tsagkozis - Cancers, 2021 - mdpi.com
Simple Summary Ewing sarcoma is a highly aggressive malignancy affecting primarily
children and adolescents. It is the second most common bone sarcoma among children …

SELNET clinical practice guidelines for bone sarcoma

JY Blay, E Palmerini, J Bollard, S Aguiar… - Critical Reviews in …, 2022 - Elsevier
Bone sarcoma are infrequent diseases, representing< 0.2% of all adult neoplasms. A
multidisciplinary management within reference centers for sarcoma, with discussion of the …

[HTML][HTML] Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the …

ADJ Pearson, N Gaspar, K Janeway… - European Journal of …, 2022 - Elsevier
Abstract The eighth Paediatric Strategy Forum focused on multi-targeted kinase inhibitors
(mTKIs) in osteosarcoma and Ewing sarcoma. The development of curative, innovative …

SARC025 arms 1 and 2: A phase 1 study of the poly (ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing …

R Chugh, KV Ballman, LJ Helman, S Patel… - Cancer, 2021 - Wiley Online Library
Background In preclinical Ewing sarcoma (ES) models, poly (adenosine diphosphate
ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with …

[PDF][PDF] Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody …

P Schöffski, CC Wang, MP Schöffski… - Oncology Research and …, 2024 - karger.com
Background: Topoisomerase I is an enzyme that plays a crucial part in DNA replication and
transcription by the relaxation of supercoiled double-stranded DNA. Topoisomerase I …